Search research articles
Contact Us
Filters
Showing results (231-240 of 293) with videos related to
Page
of 30
Sort By:
Annals of Hematology
|
October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Reid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Cancer Immunology Research
|
November 19, 2016
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M Awad, Robert E Jones, Hongye Liu, et al.
Blood
|
April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand, Yi-Bin Chen, Robert A Redd, et al.
NPJ Breast Cancer
|
December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Nature
|
May 4, 2022
Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanoma
Giacomo Oliveira, Kari Stromhaug, Nicoletta Cieri, et al.
Blood
|
January 17, 2016
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, et al.
Nature Immunology
|
February 20, 2019
Subsets of exhausted CD8<sup>+</sup> T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C Miller, Debattama R Sen, Rose Al Abosy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Journal for Immunotherapy of Cancer
|
May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Janis M Taube, Guray Akturk, Michael Angelo, et al.
Cancer Discovery
|
October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
Esra A Akbay, Shohei Koyama, Julian Carretero, et al.
Page
of 30
Search research articles
Search
Showing results (231-240 of 293) with videos related to
Sort By:
Page
of 30
Annals of Hematology
|
October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Reid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Cancer Immunology Research
|
November 19, 2016
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M Awad, Robert E Jones, Hongye Liu, et al.
Blood
|
April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand, Yi-Bin Chen, Robert A Redd, et al.
NPJ Breast Cancer
|
December 30, 2022
A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013
Foluso O Ademuyiwa, Feng Gao, Cherease R Street, et al.
Nature
|
May 4, 2022
Landscape of helper and regulatory antitumour CD4<sup>+</sup> T cells in melanoma
Giacomo Oliveira, Kari Stromhaug, Nicoletta Cieri, et al.
Blood
|
January 17, 2016
Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease
Bjoern Chapuy, Hongwei Cheng, Akira Watahiki, et al.
Nature Immunology
|
February 20, 2019
Subsets of exhausted CD8<sup>+</sup> T cells differentially mediate tumor control and respond to checkpoint blockade
Brian C Miller, Debattama R Sen, Rose Al Abosy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 3, 2018
Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma
Margaretha G M Roemer, Robert A Redd, Fathima Zumla Cader, et al.
Journal for Immunotherapy of Cancer
|
May 17, 2020
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Janis M Taube, Guray Akturk, Michael Angelo, et al.
Cancer Discovery
|
October 1, 2013
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors
Esra A Akbay, Shohei Koyama, Julian Carretero, et al.
Page
of 30